Healthcare
Live Price
Offline$31.48
-3.32% today
1Y Change
+93.93%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Teva Pharmaceutical Industries Limited (TEVA) is a Healthcare stock with a market cap of $40.70B and listed on NYSE. The stock last traded around $31.48 and up 93.9% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +4.3%, EPS growth of +184.8%, a dividend yield of 0.0%. What stands out right now is revenue +4.3%, EPS +184.8%, free cash flow +53.3% with operating margin 19.4% and ROIC 11.5%. Valuation is more restrained than many high-expectation growth names at P/E 25.7 and price/sales 2.3. Stock Foundry combines TEVA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TEVA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TEVA Max Drawdown
-21.79%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TEVA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$15.9B
+6.4% YoY
FY Net Income
$417.0M
+117.0% YoY
Free Cash Flow
$236.0M
-77.4% YoY
Revenue Growth
+4.3%
EPS Growth
+184.8%
Gross Margin
52.0%
Net Margin
9.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 17.3B | 16.5B | 15.8B | 14.9B | 15.9B |
| Gross Profit | 8.9B | 8.1B | 7.6B | 7.0B | 7.6B |
| Operating Income | 2.2B | -303M | 433M | -2.2B | 1.7B |
| EBITDA | 3.1B | 4.4B | 1.6B | -925M | 4.4B |
| Net Income | 1.4B | -1.6B | -559M | -2.4B | 417M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3.6B | 3.3B | 3.2B | 2.8B | 2.2B |
| Total Assets | 40.7B | 39.3B | 43.5B | 44.0B | 47.7B |
| Total Liabilities | 32.8B | 33.6B | 35.4B | 35.4B | 36.4B |
| Shareholder Equity | 7.9B | 5.4B | 7.5B | 7.8B | 10.3B |
| Total Debt | 17.4B | 18.1B | 20.2B | 21.6B | 23.5B |
| Net Debt | 13.8B | 14.8B | 16.9B | 18.8B | 21.3B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
798M
-49.8% YoY
Capital Expenditures
562M
-2.6% YoY
Free Cash Flow
236M
-77.4% YoY
Key ratios
Gross Margin
52.0%
Operating Margin
19.4%
Net Margin
9.0%
ROE
20.8%
Debt / Equity
2.05x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.